Nisha Bansal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Nisha Bansal has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
Thakur Gurjeet Singh
Centre of Research Impact and Outcome, Chitkara College of Pharmacy Chitkara University, Rajpura Punjab India
12 shared publicationsM. Arockia Babu
Department of Pharmacy, School of Medical and Allied Sciences Galgotias University, Greater Noida Uttar Pradesh India
10 shared publicationsYogita Tyagi
Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Premanagar, Dehradun, Uttarakhand, 248007, India
6 shared publicationsAli M. Alaseem
Department of Pharmacology, College of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, 13317, Saudi Arabia
5 shared publicationsMohammad Fareed
Department of Basic Medical Sciences, College of Medicine AlMaarefa University, Diriyah Riyadh Saudi Arabia
5 shared publicationsGlowi Alasiri
Department of Biochemistry, College of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, 13317, Saudi Arabia
4 shared publications
Latest Publications
- 15 June 2026
- Published by Wiley in Archiv der Pharmazie
- Vol. 359 (6) , e70272
USFDA‐Approved Small Molecules in the Year 2025: Medicinal Chemistry Strategies and Trends
Small‐molecule‐based therapeutics play a vital role in drug discovery. These molecules are preferred owing to their oral bioavailability, ease of tuning the physicochemical properties, and broad target accessibility. In this review article, we have explored the small molecules approved by the US Food and Drug Administration (USFDA) in 2025. Through the analysis, we found 44 drug approvals, out of which 30 candidates were approved as new molecular entities (NMEs), while the remaining 14 were approved in the category of biologics, including 10 approved as biosimilars. Considering the therapeutic area distribution of 30 NMEs, 28 drugs are approved as monotherapy, with 10 drugs as anticancer agents, 4 drugs for genetic disorders, 2 drugs each for the conditions of immunological, respiratory, ophthalmic, and endocrine disorders, along with the treatment of cardiac and infectious diseases. The structural diversity analysis revealed that 29 approved drugs were aromatic (azaheterocycles) in nature, and 13 drugs possess at least one stereogenic center. Considering the elemental diversity, the near‐universal presence of nitrogen in the form of amines, amides, and as a heteroatom, followed by the oxygen atom. Additionally, the prevalence of 3‐ or 4‐membered carbocyclic or heterocyclic rings was found in five approved drugs. For metabolism, most drugs rely on CYP3A‐mediated metabolism, primarily through CYP3A4, CYP2D6, and CYP2C8. Collectively, the analysis and compilation of the drugs presented are expected to provide practical insights and offer guidance to medicinal chemists, biologists, and scientists associated with current drug‐discovery paradigms, making continuous strides for future medicinal chemistry innovations and evolutions.
- 15 June 2026
- Published by Wiley in Archiv der Pharmazie
- Vol. 359 (6) , e70272
USFDA‐Approved Small Molecules in the Year 2025: Medicinal Chemistry Strategies and Trends
Small‐molecule‐based therapeutics play a vital role in drug discovery. These molecules are preferred owing to their oral bioavailability, ease of tuning the physicochemical properties, and broad target accessibility. In this review article, we have explored the small molecules approved by the US Food and Drug Administration (USFDA) in 2025. Through the analysis, we found 44 drug approvals, out of which 30 candidates were approved as new molecular entities (NMEs), while the remaining 14 were approved in the category of biologics, including 10 approved as biosimilars. Considering the therapeutic area distribution of 30 NMEs, 28 drugs are approved as monotherapy, with 10 drugs as anticancer agents, 4 drugs for genetic disorders, 2 drugs each for the conditions of immunological, respiratory, ophthalmic, and endocrine disorders, along with the treatment of cardiac and infectious diseases. The structural diversity analysis revealed that 29 approved drugs were aromatic (azaheterocycles) in nature, and 13 drugs possess at least one stereogenic center. Considering the elemental diversity, the near‐universal presence of nitrogen in the form of amines, amides, and as a heteroatom, followed by the oxygen atom. Additionally, the prevalence of 3‐ or 4‐membered carbocyclic or heterocyclic rings was found in five approved drugs. For metabolism, most drugs rely on CYP3A‐mediated metabolism, primarily through CYP3A4, CYP2D6, and CYP2C8. Collectively, the analysis and compilation of the drugs presented are expected to provide practical insights and offer guidance to medicinal chemists, biologists, and scientists associated with current drug‐discovery paradigms, making continuous strides for future medicinal chemistry innovations and evolutions.
- 26 May 2026
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (11) , 17665-17675
The synergistic efficacy of lupeol and enzalutamide potentiates anticancer activity, inducing apoptosis and cell cycle arrest in breast cancer cells
Breast cancer is a leading cause of cancer and death in women. There is an urgent need to explore medicinal compounds that can enhance therapeutic effectiveness while minimizing toxicity. The present study utilized lupeol and enzalutamide combinations in luminal and triple-negative breast cancer cells to assess their efficacy on cell proliferation, apoptosis, and cell cycle progression. We performed a cell viability assay to investigate cytotoxicity using the spectrophotometric method. A combination index analysis was performed to determine synergistic dose drug combinations. Apoptosis and cell cycle analysis were performed using flow cytometry. The mRNA expression was analyzed by RT-PCR. Results indicate that lupeol + enzalutamide (Lup + Enz) significantly reduces cell viability in cancer cells compared to the treatment alone. The Caspase Glo assay revealed that Lup + Enz increased the activities of caspase 3/7 and 9 in the breast cancer cell line. Furthermore, Lup + Enz induces G1 phase arrest (≈75%) and promotes apoptosis (20%) in MCF-7 cells. mRNA expression suggests that Lup + Enz activates apoptotic mRNA expression (≈ 0.25 to threefold) in cancer cells. In conclusion, lupeol, in combination with enzalutamide, alters various hallmarks of breast cancer, like proliferation, apoptosis, and cell cycle arrest. Thus, lupeol may be a promising agent that enhances the outcomes of enzalutamide-based therapy. Further preclinical and clinical research is needed to validate the findings of this study.
- 26 May 2026
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (11) , 17665-17675
The synergistic efficacy of lupeol and enzalutamide potentiates anticancer activity, inducing apoptosis and cell cycle arrest in breast cancer cells
Breast cancer is a leading cause of cancer and death in women. There is an urgent need to explore medicinal compounds that can enhance therapeutic effectiveness while minimizing toxicity. The present study utilized lupeol and enzalutamide combinations in luminal and triple-negative breast cancer cells to assess their efficacy on cell proliferation, apoptosis, and cell cycle progression. We performed a cell viability assay to investigate cytotoxicity using the spectrophotometric method. A combination index analysis was performed to determine synergistic dose drug combinations. Apoptosis and cell cycle analysis were performed using flow cytometry. The mRNA expression was analyzed by RT-PCR. Results indicate that lupeol + enzalutamide (Lup + Enz) significantly reduces cell viability in cancer cells compared to the treatment alone. The Caspase Glo assay revealed that Lup + Enz increased the activities of caspase 3/7 and 9 in the breast cancer cell line. Furthermore, Lup + Enz induces G1 phase arrest (≈75%) and promotes apoptosis (20%) in MCF-7 cells. mRNA expression suggests that Lup + Enz activates apoptotic mRNA expression (≈ 0.25 to threefold) in cancer cells. In conclusion, lupeol, in combination with enzalutamide, alters various hallmarks of breast cancer, like proliferation, apoptosis, and cell cycle arrest. Thus, lupeol may be a promising agent that enhances the outcomes of enzalutamide-based therapy. Further preclinical and clinical research is needed to validate the findings of this study.
- Open Access
- 17 April 2026
- Published by MDPI AG in Biophysica
- Vol. 6 (2) , 34
QbD-Optimized RP-HPLC Method Development for Simultaneous Quantification of Pregabalin and Duloxetine Hydrochloride
Quality by design (QbD) is a systematic approach focused on achieving consistent, predictable quality based on predefined objectives. Unlike traditional methods, QbD prioritizes risk assessment and management, which significantly enhances the robustness of the analytical method. In this study, we initiated factor screening using a three-factor, two-level design to evaluate three independent variables: flow rate, pH, and mobile phase composition. To further investigate the interaction of these variables, we employed Central Composite Design (CCD). This allows us to apply response surface methodology to the Critical Analytical Attributes (CAAs), specifically retention time, peak area, and symmetry factor, by conforming to the method’s robustness. The combination of pregabalin and duloxetine hydrochloride (HCl) dosage form was determined using a straightforward, exact, specific, and accurate reverse-phase HPLC approach. The results showed retention times of 3.265 min and 4.318 min for duloxetine HCl and pregabalin, respectively. Pregabalin demonstrated linearity from 100 to 200 μg/mL (R2 = 0.998), whilst duloxetine HCl demonstrated linearity between 20 and 120 μg/mL (R2 = 0.997). Lower LOD values of 0.925 µg/mL and 0.853 μg/mL and LOQ values of 2.809 μg/mL and 2.587 μg/mL of pregabalin and duloxetine HCl, respectively, suggest good sensitivity for the technique. The drug content of the commercial formulation may thus be determined using the recommended method. This technique can be used for standard quality control studies to simultaneously estimate pregabalin and duloxetine HCl. The novelty of the present studies lies in the development of a robust RP-HPLC method for simultaneous estimation of pregabalin and duloxetine HCl using a systematic AQbD approach, enhancing robustness, reproducibility, and reliability, making it highly suitable for routine quality control and regulatory applications.
- 17 April 2026
- Published by MDPI AG in Biophysica
- Vol. 6 (2) , 34
Open AccessQbD-Optimized RP-HPLC Method Development for Simultaneous Quantification of Pregabalin and Duloxetine Hydrochloride
Quality by design (QbD) is a systematic approach focused on achieving consistent, predictable quality based on predefined objectives. Unlike traditional methods, QbD prioritizes risk assessment and management, which significantly enhances the robustness of the analytical method. In this study, we initiated factor screening using a three-factor, two-level design to evaluate three independent variables: flow rate, pH, and mobile phase composition. To further investigate the interaction of these variables, we employed Central Composite Design (CCD). This allows us to apply response surface methodology to the Critical Analytical Attributes (CAAs), specifically retention time, peak area, and symmetry factor, by conforming to the method’s robustness. The combination of pregabalin and duloxetine hydrochloride (HCl) dosage form was determined using a straightforward, exact, specific, and accurate reverse-phase HPLC approach. The results showed retention times of 3.265 min and 4.318 min for duloxetine HCl and pregabalin, respectively. Pregabalin demonstrated linearity from 100 to 200 μg/mL (R2 = 0.998), whilst duloxetine HCl demonstrated linearity between 20 and 120 μg/mL (R2 = 0.997). Lower LOD values of 0.925 µg/mL and 0.853 μg/mL and LOQ values of 2.809 μg/mL and 2.587 μg/mL of pregabalin and duloxetine HCl, respectively, suggest good sensitivity for the technique. The drug content of the commercial formulation may thus be determined using the recommended method. This technique can be used for standard quality control studies to simultaneously estimate pregabalin and duloxetine HCl. The novelty of the present studies lies in the development of a robust RP-HPLC method for simultaneous estimation of pregabalin and duloxetine HCl using a systematic AQbD approach, enhancing robustness, reproducibility, and reliability, making it highly suitable for routine quality control and regulatory applications.
- 16 March 2026
- Published by Wiley in Archiv der Pharmazie
- Vol. 359 (3) , e70220
Developments on BACE 1 Inhibitors as Anti‐Alzheimer Agents: A Perspective on Medicinal Chemistry‐Based Advances
Alzheimer's disease (AD) is a progressive and complicated neurodegenerative disorder that mostly affects the elderly and is characterized by memory loss, cognitive dysfunction, accumulation of amyloid beta (Aβ) plaques, neurofibrillary tangles, and cholinergic deficits. Current therapies used for AD, such as acetylcholinesterase inhibitors and NMDA receptor antagonist memantine, can only provide temporary or symptomatic relief, but they do not stop or reverse the progression of the disease. Numerous pathogenic hypotheses have been proposed to explain this mechanism; however, the amyloid cascade hypothesis remains the most widely accepted theory, as it suggests that β‐site amyloid precursor protein‐cleaving enzyme 1 (BACE1) plays a critical role in the generation of Aβ peptides. Therefore, BACE1 may be a key therapeutic target. This review primarily focuses on the key role of BACE1 in AD pathogenesis and describes the development of its inhibitors over three generations, explaining their structure, design, and pharmacological properties. While the first generation lacked brain penetration, the second‐generation improved potency but encountered clinical trial failures due to adverse effects. The third generation of these drugs was designed to achieve a balance between efficacy, selectivity, and safety. Additionally, we review the promising molecules currently under clinical investigation, highlighting both their therapeutic potential and the challenges that remain in developing effective disease‐modifying therapies for AD treatment.
- 16 March 2026
- Published by Wiley in Archiv der Pharmazie
- Vol. 359 (3) , e70220
Developments on BACE 1 Inhibitors as Anti‐Alzheimer Agents: A Perspective on Medicinal Chemistry‐Based Advances
Alzheimer's disease (AD) is a progressive and complicated neurodegenerative disorder that mostly affects the elderly and is characterized by memory loss, cognitive dysfunction, accumulation of amyloid beta (Aβ) plaques, neurofibrillary tangles, and cholinergic deficits. Current therapies used for AD, such as acetylcholinesterase inhibitors and NMDA receptor antagonist memantine, can only provide temporary or symptomatic relief, but they do not stop or reverse the progression of the disease. Numerous pathogenic hypotheses have been proposed to explain this mechanism; however, the amyloid cascade hypothesis remains the most widely accepted theory, as it suggests that β‐site amyloid precursor protein‐cleaving enzyme 1 (BACE1) plays a critical role in the generation of Aβ peptides. Therefore, BACE1 may be a key therapeutic target. This review primarily focuses on the key role of BACE1 in AD pathogenesis and describes the development of its inhibitors over three generations, explaining their structure, design, and pharmacological properties. While the first generation lacked brain penetration, the second‐generation improved potency but encountered clinical trial failures due to adverse effects. The third generation of these drugs was designed to achieve a balance between efficacy, selectivity, and safety. Additionally, we review the promising molecules currently under clinical investigation, highlighting both their therapeutic potential and the challenges that remain in developing effective disease‐modifying therapies for AD treatment.
- Open Access
- 13 February 2026
- Published by MDPI AG in Biophysica
- Vol. 6 (1) , 12
Autophagy–Proteasome Crosstalk in Neurodegenerative Diseases: Cellular Proteostasis, Neural Interactions, and Therapeutic Implications
Neurodegenerative conditions such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and amyotrophic lateral sclerosis (ALS) are devastating disorders with the gradual loss of neurons and cognitive or motor disability. This is a review article that develops the crucial functions of autophagy and proteostasis within the scope of the neurodegenerative disease. Autophagy is a very well-conserved cell process that poses a quality control checkpoint that allows for the degradation and recycling of damaged organelles and misfolded proteins. Chaperones, the ubiquitin–proteasome complexes, and endoplasmic reticulum-associated degradation (ERAD) are also referred to as proteostasis, which plays a key role in ensuring the correct protein folding properties and the prevention of toxic protein accumulation. This article offers a detailed discussion of the relationship between autophagy and proteostasis, illustrating the mechanisms of mutual cooperation of these processes, ensuring cellular homeostasis and inhibiting the formation of pathogenic protein aggregates. In addition, this review includes experimental data during preclinical studies and clinical trials and expounds on the therapeutic opportunities that show the potential of targeting autophagy and proteostasis to counter neurodegenerative disorders. Although research progress creates potential for new indicators, the issues and difficulties relating to the effects of regulating such complex cellular pathways are also discussed in the article. Finally, the review can add to the research of neurodegenerative disease mechanisms of autophagy and proteostasis as well as provide insights about the future of treatment and its implementation.
- 13 February 2026
- Published by MDPI AG in Biophysica
- Vol. 6 (1) , 12
Open AccessAutophagy–Proteasome Crosstalk in Neurodegenerative Diseases: Cellular Proteostasis, Neural Interactions, and Therapeutic Implications
Neurodegenerative conditions such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and amyotrophic lateral sclerosis (ALS) are devastating disorders with the gradual loss of neurons and cognitive or motor disability. This is a review article that develops the crucial functions of autophagy and proteostasis within the scope of the neurodegenerative disease. Autophagy is a very well-conserved cell process that poses a quality control checkpoint that allows for the degradation and recycling of damaged organelles and misfolded proteins. Chaperones, the ubiquitin–proteasome complexes, and endoplasmic reticulum-associated degradation (ERAD) are also referred to as proteostasis, which plays a key role in ensuring the correct protein folding properties and the prevention of toxic protein accumulation. This article offers a detailed discussion of the relationship between autophagy and proteostasis, illustrating the mechanisms of mutual cooperation of these processes, ensuring cellular homeostasis and inhibiting the formation of pathogenic protein aggregates. In addition, this review includes experimental data during preclinical studies and clinical trials and expounds on the therapeutic opportunities that show the potential of targeting autophagy and proteostasis to counter neurodegenerative disorders. Although research progress creates potential for new indicators, the issues and difficulties relating to the effects of regulating such complex cellular pathways are also discussed in the article. Finally, the review can add to the research of neurodegenerative disease mechanisms of autophagy and proteostasis as well as provide insights about the future of treatment and its implementation.
- 20 January 2026
- Published by Wiley in Archiv der Pharmazie
- Vol. 359 (1) , e70190
Retrospection of the USFDA‐Approved Halogenated Drugs and Their Implication in Medicinal Chemistry and Drug Discovery: A Perspective of Approved Drugs Between 2019 and 2024
Halogens are utilized in drug discovery and development due to their ability to precisely tune the molecular properties of drug candidates. The halogen substituents play a crucial role in determining the stability, lipophilicity, and receptor binding, as well as significantly influencing the metabolic fate of the drug candidates. Literature insights reveal that 30% of all small molecules approved by the USFDA carry a halogen as a substituent. Considering the vital importance of halogen‐containing substituents, we have compiled concise information on halogen‐containing US FDA‐approved drugs over the last decade (2019–2024). The articles provide information on pharmacological conditions, targets, available formulations, and pharmacokinetic details for each approved drug that possesses a halogen as a substituent, along with its corresponding chemical structure. The analysis revealed that 37 new drugs were approved to combat cancer (13), followed by rare diseases (6), viral infections (3), and other conditions during the analysis period. Furthermore, the chemistry of halogens, along with their medicinal applications, provides key evidence on how halogens have been explored to enhance the pharmacokinetics and pharmacodynamics of drug candidates. The analysis of approved dosage forms revealed that 23 were solid dosage forms, comprising 24 tablet forms, 8 capsules, and 1 powder. CYP3A4 is a major contributor in the metabolism of 6 drugs, followed by CYP3A (3), CYP1A2 (2), CYP3A4/5 (2), and one each by CYP2C9, UGT1A9, CYP2C8, aldehyde oxidase, and other non‐CYP enzymes. The present medicinal chemistry perspective is thus expected to be a valuable read for the medicinal and allied sciences community.
- 20 January 2026
- Published by Wiley in Archiv der Pharmazie
- Vol. 359 (1) , e70190
Retrospection of the USFDA‐Approved Halogenated Drugs and Their Implication in Medicinal Chemistry and Drug Discovery: A Perspective of Approved Drugs Between 2019 and 2024
Halogens are utilized in drug discovery and development due to their ability to precisely tune the molecular properties of drug candidates. The halogen substituents play a crucial role in determining the stability, lipophilicity, and receptor binding, as well as significantly influencing the metabolic fate of the drug candidates. Literature insights reveal that 30% of all small molecules approved by the USFDA carry a halogen as a substituent. Considering the vital importance of halogen‐containing substituents, we have compiled concise information on halogen‐containing US FDA‐approved drugs over the last decade (2019–2024). The articles provide information on pharmacological conditions, targets, available formulations, and pharmacokinetic details for each approved drug that possesses a halogen as a substituent, along with its corresponding chemical structure. The analysis revealed that 37 new drugs were approved to combat cancer (13), followed by rare diseases (6), viral infections (3), and other conditions during the analysis period. Furthermore, the chemistry of halogens, along with their medicinal applications, provides key evidence on how halogens have been explored to enhance the pharmacokinetics and pharmacodynamics of drug candidates. The analysis of approved dosage forms revealed that 23 were solid dosage forms, comprising 24 tablet forms, 8 capsules, and 1 powder. CYP3A4 is a major contributor in the metabolism of 6 drugs, followed by CYP3A (3), CYP1A2 (2), CYP3A4/5 (2), and one each by CYP2C9, UGT1A9, CYP2C8, aldehyde oxidase, and other non‐CYP enzymes. The present medicinal chemistry perspective is thus expected to be a valuable read for the medicinal and allied sciences community.
- 27 November 2025
- Published by Wiley in Luminescence
- Vol. 40 (12) , e70368
Acid Vapor Responsive Coumarin Coupled Imidazole as Colorimetric and Fluorometric Co 2+ Sensor, DFT, and Zebrafish Bioimaging Studies
This work describes a novel Co 2+ ion sensor 3‐(2‐(2‐(4‐nitrophenyl)‐4,5‐diphenyl‐1 H ‐imidazol‐1‐yl)thiazol‐4‐yl)‐2 H ‐chromen‐2‐one ( NBIC ) comprising imidazole and a coumarin‐thiazole moiety. When Co 2+ is present, NBIC shows a notable quenching of fluorescence at 450 nm as a result of complex formation. The limit of detection was found to be 7 μM under optimal conditions. It was discovered that the sensor was quite selective for Co 2+ ions despite many competing ions. The chemosensor NBIC also exhibited colorimetric and fluorometric sensing ability with a visible colorimetric response to trifluoroacetic acid (TFA). The Job's plot validates the 1:1 binding stoichiometry between Co 2+ and NBIC . Further, the study was also validated with zebrafish bioimaging studies.
- 27 November 2025
- Published by Wiley in Luminescence
- Vol. 40 (12) , e70368
Acid Vapor Responsive Coumarin Coupled Imidazole as Colorimetric and Fluorometric Co 2+ Sensor, DFT, and Zebrafish Bioimaging Studies
This work describes a novel Co 2+ ion sensor 3‐(2‐(2‐(4‐nitrophenyl)‐4,5‐diphenyl‐1 H ‐imidazol‐1‐yl)thiazol‐4‐yl)‐2 H ‐chromen‐2‐one ( NBIC ) comprising imidazole and a coumarin‐thiazole moiety. When Co 2+ is present, NBIC shows a notable quenching of fluorescence at 450 nm as a result of complex formation. The limit of detection was found to be 7 μM under optimal conditions. It was discovered that the sensor was quite selective for Co 2+ ions despite many competing ions. The chemosensor NBIC also exhibited colorimetric and fluorometric sensing ability with a visible colorimetric response to trifluoroacetic acid (TFA). The Job's plot validates the 1:1 binding stoichiometry between Co 2+ and NBIC . Further, the study was also validated with zebrafish bioimaging studies.
- 25 October 2025
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 132, 118451
Pharmacophore-based high-throughput virtual screening (HTVS) to identify new c-Src kinase inhibitors with anticancer potential
- 25 October 2025
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 132, 118451
Pharmacophore-based high-throughput virtual screening (HTVS) to identify new c-Src kinase inhibitors with anticancer potential